Work

Dacomitinib (D) Versus Erlotinib (E) in 2Nd/3Rd Line Nsclc: Outcome for Asian Patients from the Archer 1009 Global Phase 3 Trial

Year: 2014

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu349.22

Authors: T. Mok, K.J. O'Byrne, S.S. Ramalingam, P.A. Janne, M. Boyer, J.S. Ahn, H. Zhang, J. O'Connell, I. Taylor, C. Mather, L. Paz-Ares

Institutions: Chinese University of Hong Kong, Princess Alexandra Hospital, Winship Cancer Institute, Dana-Farber Cancer Institute, Royal Prince Alfred Hospital, Samsung Medical Center, Pfizer (China), Pfizer (United States), Hospital Universitario Virgen del Rocío

Language: French

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W1954013379

FWCI:

Cites:

Cited by:

Related to: 10